Compass Therapeutics Court & Legal Update
Compass Therapeutics received regulatory feedback from the FDA recommending a new clinical trial to demonstrate survival benefit before submitting a Biologics License Application (BLA) for tovecimig in biliary tract cancer. The company disagrees with the recommendation, citing statistically significant improvements in objective response rate and progression-free survival from its Phase 2/3 COMPANION-002 study. Compass intends to further engage with the FDA to determine the path forward for its planned BLA submission.
- Counterparty
- FDA